Procomvax

RSS

Expired

This medicine's authorisation has expired

haemophilus B conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine
MedicineHumanExpired

Norwegian is available via eTranslation, the European Commission's machine translation service.

Translate to Norwegian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

Sanofi Pasteur MSD S.N.C., the marketing authorisation holder (MAH) for Procomvax, has decided, for commercial reasons, not to apply for the second renewal of the marketing authorisation for this medicinal product. Consequently, the marketing authorisation for Procomvax expired on 14 May 2009. The MAH has confirmed that this decision is not related to any safety concerns. 

Procomvax (Haemophilus influenzae type b and hepatitis B vaccine) was indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants six weeks to 15 months of age. It was authorised by the European Commission on 7 May 1999. 

The marketing authorisation was first renewed for five years on 14 May 2004. Alternative vaccines containing the same active substances as Procomvax are available throughout the European Union.

български (BG) (471.53 KB - PDF)

Vis

español (ES) (560.56 KB - PDF)

Vis

čeština (CS) (430.19 KB - PDF)

Vis

dansk (DA) (277.14 KB - PDF)

Vis

Deutsch (DE) (280.82 KB - PDF)

Vis

eesti (ET) (295.19 KB - PDF)

Vis

ελληνικά (EL) (455.37 KB - PDF)

Vis

français (FR) (278.01 KB - PDF)

Vis

italiano (IT) (277.41 KB - PDF)

Vis

latviešu (LV) (445.93 KB - PDF)

Vis

lietuvių (LT) (391.5 KB - PDF)

Vis

magyar (HU) (409.34 KB - PDF)

Vis

Malti (MT) (418.99 KB - PDF)

Vis

Nederlands (NL) (279.98 KB - PDF)

Vis

polski (PL) (462.1 KB - PDF)

Vis

português (PT) (280.39 KB - PDF)

Vis

română (RO) (387.58 KB - PDF)

Vis

slovenčina (SK) (414.04 KB - PDF)

Vis

slovenščina (SL) (404.36 KB - PDF)

Vis

suomi (FI) (295.82 KB - PDF)

Vis

svenska (SV) (277.19 KB - PDF)

Vis

Product information

български (BG) (944.25 KB - PDF)

Vis

español (ES) (1.08 MB - PDF)

Vis

čeština (CS) (704.2 KB - PDF)

Vis

dansk (DA) (428.1 KB - PDF)

Vis

Deutsch (DE) (424.82 KB - PDF)

Vis

eesti (ET) (465.7 KB - PDF)

Vis

ελληνικά (EL) (267.58 KB - PDF)

Vis

français (FR) (429.92 KB - PDF)

Vis

italiano (IT) (436.98 KB - PDF)

Vis

latviešu (LV) (788.42 KB - PDF)

Vis

lietuvių (LT) (468.31 KB - PDF)

Vis

magyar (HU) (672.82 KB - PDF)

Vis

Malti (MT) (729.44 KB - PDF)

Vis

Nederlands (NL) (436.53 KB - PDF)

Vis

polski (PL) (791.87 KB - PDF)

Vis

português (PT) (433.54 KB - PDF)

Vis

română (RO) (468.58 KB - PDF)

Vis

slovenčina (SK) (699.48 KB - PDF)

Vis

slovenščina (SL) (677.22 KB - PDF)

Vis

suomi (FI) (476.68 KB - PDF)

Vis

svenska (SV) (421.35 KB - PDF)

Vis
Latest procedure affecting product information:II/0028
11/12/2007
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

español (ES) (576.22 KB - PDF)

Vis

čeština (CS) (350.49 KB - PDF)

Vis

dansk (DA) (576.59 KB - PDF)

Vis

Deutsch (DE) (327.66 KB - PDF)

Vis

eesti (ET) (323.28 KB - PDF)

Vis

ελληνικά (EL) (107.98 KB - PDF)

Vis

français (FR) (319.29 KB - PDF)

Vis

italiano (IT) (327.04 KB - PDF)

Vis

latviešu (LV) (358.41 KB - PDF)

Vis

lietuvių (LT) (342.45 KB - PDF)

Vis

magyar (HU) (349.29 KB - PDF)

Vis

Nederlands (NL) (327.77 KB - PDF)

Vis

polski (PL) (362.15 KB - PDF)

Vis

português (PT) (320.27 KB - PDF)

Vis

slovenčina (SK) (350.93 KB - PDF)

Vis

slovenščina (SL) (328.4 KB - PDF)

Vis

suomi (FI) (321.96 KB - PDF)

Vis

svenska (SV) (318.76 KB - PDF)

Vis

Product details

Name of medicine
Procomvax
Active substance
  • polyribosylribitol phosphate from Haemophilus influenzae type b as PRP-OMPC
  • outer membrane protein complex of Neisseria meningitidis (outer membrane protein complex of the B11 strain of Neisseria meningitidis subgroup B)
  • adsorbed hepatitis B surface antigen produced in recombinant yeast cells (Saccharomyces cerevisiae)
International non-proprietary name (INN) or common name
haemophilus B conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine
Therapeutic area (MeSH)
  • Hepatitis B
  • Meningitis, Haemophilus
  • Immunization
Anatomical therapeutic chemical (ATC) code
J07CA

Pharmacotherapeutic group

Vaccines

Therapeutic indication

PROCOMVAX is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age.

Authorisation details

EMA product number
EMEA/H/C/000231
Marketing authorisation holder
Sanofi Pasteur MSD, SNC

Sanofi Pasteur MSD SNC
8 rue Jonas Salk
F-69007 Lyon
FRANCE

Marketing authorisation issued
07/05/1999
Expiry of marketing authorisation
14/05/2009
Revision
9

Assessment history

español (ES) (621 KB - PDF)

Vis

čeština (CS) (386.12 KB - PDF)

Vis

dansk (DA) (263.16 KB - PDF)

Vis

Deutsch (DE) (264.2 KB - PDF)

Vis

eesti (ET) (277.53 KB - PDF)

Vis

ελληνικά (EL) (158.47 KB - PDF)

Vis

français (FR) (263.77 KB - PDF)

Vis

italiano (IT) (262.66 KB - PDF)

Vis

latviešu (LV) (426.22 KB - PDF)

Vis

lietuvių (LT) (342.86 KB - PDF)

Vis

magyar (HU) (394.28 KB - PDF)

Vis

Nederlands (NL) (266.58 KB - PDF)

Vis

polski (PL) (436.4 KB - PDF)

Vis

português (PT) (262.09 KB - PDF)

Vis

slovenčina (SK) (360.23 KB - PDF)

Vis

slovenščina (SL) (377.57 KB - PDF)

Vis

suomi (FI) (282.3 KB - PDF)

Vis

svenska (SV) (261.15 KB - PDF)

Vis

This page was last updated on

Share this page